| Literature DB >> 35497846 |
Thanawat Suwatthanarak1, Masayoshi Tanaka1, Taisuke Minamide1, Andrew J Harvie2,3, Abiral Tamang2, Kevin Critchley2, Stephen D Evans2, Mina Okochi1.
Abstract
Quantum dots (QDs) are promising nanomaterials due to their unique photophysical properties. For them to be useful in biological applications, the particle surface generally needs to be conjugated to biological molecules, such as antibodies. In this study, we screened CdTe/CdS QD-binding peptides from a phage display library as linkers for simple and bio-friendly QD modification. Among five QD-binding peptide candidates, a series of truncated peptides designed from two high-affinity peptides were subjected to an array-based binding assay with QDs to assess their functional core sequences and characteristics. Linking these isolated, shortened peptides (PWSLNR and SGVYK) with an antibody-binding peptide (NKFRGKYK) created dual-functional peptides that are capable of QD surface functionalisation by antibodies. Consequently, the dual-functional peptides could mediate anti-CD9 antibody functionalisation onto CdTe/CdS QD surface; CD9 protein imaging of cancer cells was also demonstrated. Our proposed peptides offer an effective vehicle for QD surface functionalisation in biological applications. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35497846 PMCID: PMC9049935 DOI: 10.1039/d0ra00460j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1(i) and (ii) TEM images of prepared CdTe/CdS QDs. (iii) Fluorescence image of peptide array of P1–P6 after binding assay with CdTe/CdS QD (100 nM). For clarity, the image is presented in negative. (iv) Spot intensity profile of (iii). Error bars denote the standard deviation of triplicate results.
A list of peptides used in this studya
| Peptide | Sequence | pI | GRAVY | Note |
|---|---|---|---|---|
| P1 | GDGNSVLKPGNW | 5.84 | −0.908 | Screened with 3/7 frequency |
| P2 | TLTSETPWSLNR | 5.66 | −0.842 | Screened with 1/7 frequency |
| P3 | YPSSLNINASSF | 5.52 | −0.017 | Screened with 1/7 frequency |
| P4 | SGVYKVAYDWQH | 6.46 | −0.717 | Screened with 1/7 frequency |
| P5 | SHALQGPEGTAT | 5.22 | −0.617 | Screened with 1/7 frequency |
| P6 | AAAA | 3.69 | 1.800 | Negative control |
| P7 | PWSLNR | 10.18 | −1.250 | Truncated from P2 |
| P8 | SGVYK | 8.31 | −0.440 | Truncated from P4 |
| P9 | NKFRGKYKGGGPWSLNR | 11.17 | −1.606 | Dual-functionalised from P7 |
| P10 | NKFRGKYKGGGSGVYK | 10.30 | −1.375 | Dual-functionalised from P8 |
pI and GRAVY were calculated from ProtParam tool (http://web.expasy.org/protparam/).[26]
Fig. 2Truncation results after binding assay between peptide array of truncated sequences with CdTe/CdS QDs. (i) P2 (TLTSETPWSLNR) and (ii) P4 (SGVYKVAYDWQH). The peptide array of truncated sequences was synthesised and used in the binding assay with CdTe/CdS QD (100 nM). Original P2 and P4 were defined to have a relative spot intensity of 100%.
Fig. 3Plot of spot fluorescence intensity against QD concentration for KD determination. The peptide arrays of P7 (PWSLNR) and P8 (SGVYK) were synthesised and used in binding assays with CdTe/CdS QDs at different concentrations (0–200 nM). The solid lines are Hill equation-fitted curves. Error bars indicate the standard deviation of triplicate results.
Fig. 4(i) Schematic illustration of QD surface modification using the dual-functional peptide. (ii) SPR sensorgram from a CD9 antibody-immobilised sensor chip when flowed with dual-functional peptides (70 s) and CdTe/CdS QDs (560 s). (iii) CD9 imaging of MDA-MB-231 cancer cells using (a and b) dual-functional peptides (P9 and P10), (c) a commercial secondary antibody, and (d) a negative control peptide (P6). Inserts are overlays of brightfield and fluorescence images.